Interaction between proteins and chemical compounds is an inherently complex problem which is of significant importance to research and development processes across a broad range of sectors. Moleculomics have developed powerful structural modelling and virtual screening platforms capable of simulating real life conditions by virtue of increased understanding of molecular interaction at the whole system level.
The Moleculomics technologies utilize the latest High Performance Computing approaches and are applied extensively to wild type, mutations and polymorphic variation within organisms. They are used to identify interactions, not only at the targets of interest, but also elsewhere across the entire proteome or across several proteomes.
Increased scale of understanding of molecular interaction enables research and development times to be reduced by more rapid and wider identification of target hits while simultaneously reducing the risk of adverse or off-target interactions.
Moleculomics is the only company offering open-ended lead discovery, toxicity screening and protein network identification, that is completely unlimited in reach, and that is applied across multiple genomes.
With offices in both the UK and North America, the Swansea headquartered company employs 8 people and has established itself as one of the leading commercial structural bioinformatics system teams. More information about the Moleculomics team can be found here.
Moleculomics technologies have been extensively validated through cutting edge contract research as identified below;
Our approach to consultancy and outsourced work is flexible and collaborative. Our company values recognise the importance of confidentiality – our services are hosted by proprietary software and project-dedicated hardware. It is our strategy to help develop and enhance intellectual property through trusted partnership.